Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
about
Natalizumab for relapsing remitting multiple sclerosisTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsJC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?The changing landscape of progressive multifocal leukoencephalopathy.Best practice in the use of natalizumab in multiple sclerosis.Infection risk in patients on multiple sclerosis therapeutics.Effects of natalizumab treatment on Foxp3+ T regulatory cells.Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectSevere haematological complications during treatment with natalizumab.Progressive multifocal leukoencephalopathy in HIV-1 infection.Progressive multifocal leucoencephalopathy in an immunocompetent patient with favourable outcome. A case report.Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokineticsEscalating immunotherapy of multiple sclerosis.Natalizumab in the treatment of multiple sclerosisTherapeutic strategies in childhood multiple sclerosisExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Treating multiple sclerosis with monoclonal antibodies.JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Natalizumab for the treatment of relapsing multiple sclerosis.Randomized controlled trial design in rheumatoid arthritis: the past decade.Treating multiple sclerosis with monoclonal antibodies: a 2010 update.Progressive multifocal leukoencephalopathy: what's new?Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.Innovative monoclonal antibody therapies in multiple sclerosis.Managing MS in a changing treatment landscape.Progressive multifocal leukoencephalopathy and natalizumab.Treating multiple sclerosis with natalizumab.Multiple sclerosis (MS) for the urologist: What should urologists know about MS?Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update.Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.Seroprevalence rates of BKV, JCV, and MCPyV polyomaviruses in the general Czech Republic population.Activities of different classes of acyclic nucleoside phosphonates against BK virus in primary human renal cells.Natalizumab: benefit outweighs risk in selected patients with multiple sclerosis.Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.
P2860
Q24235861-3F3C93EE-AB1C-42C9-9E56-148838173DADQ26823444-9820732E-1120-4231-BC24-0713C756F2D2Q26852060-D221FE82-30BB-4EA3-9F4C-59D0B1DF3BE4Q30403035-CC9EDBE6-9C4A-4C8C-9DC8-13DFA7AAE3C1Q30597618-0EDB9445-70FB-4F16-ACDD-6B22A9A4C07DQ30908652-8F96AEBA-197E-4C22-9802-27309D707668Q33373995-6F670A17-EE8F-41A6-AB08-A321B194C514Q33383576-D9193048-2030-4464-A9DA-B08C9B51A98BQ33400350-E29FA430-4A76-43E9-9049-D9F955086A53Q33506561-97E030B2-AA5E-4FB4-8A93-85848EB78291Q33581135-F440F1DE-86BD-4681-81F9-1889AF8A68E9Q33714913-4D5F4F1D-C2EA-4AC4-8222-0DF8FA9FA3EEQ34409100-196DADFF-A891-4C9A-9F64-843C3C6948BDQ34409340-53A327D8-AFBE-48E5-BF96-61388AF196C1Q34409508-144E7FC9-BA5A-43D4-9F0C-D1C8B846D25EQ35589934-CDA510DE-507A-409F-9165-2DC03BE4A0DDQ35609239-9CF70A6D-03A2-408E-9607-B69E2034B836Q36508862-2C852D95-0ABB-4C79-8F34-A43393C5B949Q36748702-A724736D-BF5C-4FF8-9A7F-DD37134A959DQ37111904-29CE8E17-AEF0-4826-9A5B-A0A9CC576B92Q37157144-CDE266D4-361F-4EE7-85D1-C1AC4ACC5D5CQ37180600-E1350343-5036-45FA-A9B2-FD77CBEB7C7AQ37290643-84347F56-A1E6-4FFD-819A-DC6D6564C044Q37397646-FA2F1CAC-B6B8-46A6-940B-794657A97F1EQ37737305-D749D360-74B1-45F2-9521-AC61732B753EQ37755922-DE604480-D62F-46A6-A337-148401700D96Q37778944-6B9FA8EE-26BB-47B9-BE87-B4CBCAD29AB7Q37814815-55DC6127-5B1A-4120-B7C7-743091BBC346Q37823315-6B906207-CA42-4E94-B103-9464CA42B421Q37857752-4CE83120-7AC6-4E14-BC5D-D07C0003BABDQ37885823-0B1D1ED3-C029-47E6-9322-EC9744E7E5D3Q37957123-81A417D4-AD89-41F4-9663-97EE73F07FF0Q38331840-C9D43E0B-2C9A-4AB3-B30E-F224D104C672Q38616689-E5EB4652-F51E-44A8-9F95-086D1FD49E03Q38793624-B78F5F8A-D359-4151-8817-FEE7450CF148Q39064776-706EED8B-C482-4420-96FD-30DE7615B053Q39587782-1292B5C5-72AF-4878-934D-209D1DF3F2A9Q41173582-462FF45E-4FE8-4A08-9CFA-2BD134C4C075Q41386664-7466CC92-9230-4299-A169-50187F0E0C7AQ44272607-A5846AAE-C745-41D4-B022-22DB4D09866E
P2860
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Natalizumab treatment for mult ...... ient selection and monitoring.
@ast
Natalizumab treatment for mult ...... ient selection and monitoring.
@en
Natalizumab treatment for mult ...... ient selection and monitoring.
@nl
type
label
Natalizumab treatment for mult ...... ient selection and monitoring.
@ast
Natalizumab treatment for mult ...... ient selection and monitoring.
@en
Natalizumab treatment for mult ...... ient selection and monitoring.
@nl
prefLabel
Natalizumab treatment for mult ...... ient selection and monitoring.
@ast
Natalizumab treatment for mult ...... ient selection and monitoring.
@en
Natalizumab treatment for mult ...... ient selection and monitoring.
@nl
P2093
P50
P1433
P1476
Natalizumab treatment for mult ...... ient selection and monitoring.
@en
P2093
Chris H Polman
David B Clifford
David Bates
David Miller
Ernst Wilhelm Radue
Eugene O Major
Eva Havrdova
Mads Ravnborg
Paul W O'Connor
P304
P356
10.1016/S1474-4422(07)70078-9
P577
2007-05-01T00:00:00Z